The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved ...

Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer ...

The innovative GO chip, developed at the University of Michigan, represents a significant leap in lung cancer treatment by ...

The FDA has approved Tislelizumab (Tevimbra) plus platinum-based chemotherapy as a first-line treatment for adult patients ...

AstraZeneca announced that a durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for ...

The European Medicines Agency (EMA) committee (CHMP) has recommended approving trastuzumab deruxtecan (Enhertu), a ...

The early findings from the SERENA-6 trial indicate that the investigational oral SERD camizestrant provides a “highly ...

Regeneron Pharmaceuticals, announced that FDA accepted its resubmitted Biologics License Application for odronextamab, a ...

KEYTRUDA® (pembrolizumab) plus standard care for resectable locally advanced head and neck squamous cell carcinoma receives FDA priority review based on KEYNOTE-689 results. The trial showed improved ...

Francis Medical, developing water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer, announced the completion of patient enrollment and initial treatments in its VAPOR 2 ...